Gene · 7335
UBE2V1: ubiquitin conjugating enzyme E2 V1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. UBE2V1: ubiquitin conjugating enzyme E2 V1. Genes, record 7335. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7335
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q13404 | Ubiquitin-conjugating enzyme E2 variant 1 | 147 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents17
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 69040 | Q13404 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 8993 | Q13404 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 8993 | Q13404 | Espacenet |
| US 11892452 B2 | 2024-02-06 | 31 | Q13404 | Espacenet |
| JP 2023550743 A | 2023-12-05 | 99 | Q13404 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 95075 | Q13404 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 741 | Q13404 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 198046 | Q13404 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 12246 | Q13404 | Espacenet |
| US 11016093 B2 | 2021-05-25 | 31 | Q13404 | Espacenet |
1 to 10 of 17
See all 17 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,183
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | UBE2V1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 13 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 5 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| R01AI060025 | From Drosophila Immunity to Anti-Inflammatories | 4 | 2025 |
| P01CA019014 | Viral Oncogenesis, Latency, and Replication | 3 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 3 | 2025 |
| R01DE017336 | Epigenetic Regulation of Epstein-Barr Virus | 3 | 2025 |
| R01GM065334 | Solution structure and dynamics of polyubiquitin chains | 3 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 3 | 2025 |
1 to 10 of 1,183Source NIH's project files
See all 1,183 nih grantsPapers1,504
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Type I collagen promotes triple-negative breast cancer progression through a UBE2V1-ACSL5 regulatory axis. | Front Oncol | 2026 | 42755793 | PubTator, text mining | PubMed |
| Small-molecule disruption of the TRAF6-Ubc13 protein-protein interaction: targeting noncanonical ubiquitin signaling in inflammation and cancer. | Biochem Pharmacol | 2026 | 42660298 | PubTator, text mining | PubMed |
| BRD4-mediated histone H4K12 lactylation drives ovarian cancer progression by activating the Ube2v1-DDX3X ubiquitination axis. | J Transl Med | 2026 | 42374413 | PubTator, text mining | PubMed |
| BMS-CTMC-2025-461Ubiquitin as a Putative Causal Immune Orchestrator in Initial COVID-19 Severity: A Mendelian Randomization and Multi-Omics Study. | Curr Top Med Chem | 2026 | 42300294 | PubTator, text mining | PubMed |
| CircRNA-cZFR is upregulated in bladder cancer and promotes tumorigenesis via UBE2V1 regulation. | Sci Rep | 2026 | 42215525 | PubTator, text mining | PubMed |
| CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer. | Cell Death Dis | 2026 | 41888115 | PubTator, text mining | PubMed |
| Moonlighting cytosolic function of ACAD9: suppression of TRAF6-mediated osteoclastogenesis and protection against osteoporosis. | Cell Death Dis | 2026 | 41888097 | PubTator, text mining | PubMed |
| Uev1A counteracts oncogenic Ras stimuli in both polyploid and diploid cells. | Elife | 2026 | 41879050 | PubTator, text mining | PubMed |
| EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer. | Mol Ther Oncol | 2026 | 41732759 | PubTator, text mining | PubMed |
| The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications. | Front Immunol | 2026 | 41727427 | PubTator, text mining | PubMed |
1 to 10 of 1,504
See all 1,504 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7335
GET https://conductscience.org/api/genes/v1/7335/patents